Molecular Partners AG is a clinical-stage biotechnology company founded in 2004 as a spin-off from the University of Zurich and headquartered in Zurich-Schlieren, Switzerland, with US operations in Concord, Massachusetts. The company pioneered DARPin (Designed Ankyrin Repeat Protein) therapeutics. In October 2026, Molecular Partners announced a strategic pivot to transform into a dedicated targeted radiopharmaceuticals biotech, prioritizing its lead clinical DLL3 Radio-DARPin candidate MP0712 co-developed with Orano Med, while initiating a restructuring cutting up to 44% of headcount (no more than 55 roles).
Initial Phase 1/2a safety data presentation for MP0712 at North America Conference on Lung Cancer
Expected completion of workforce restructuring and Swiss consultation process
Clinical-stage biotech Molecular Partners initiated a corporate restructuring to cut up to 55 positions (~44% of workforce) under Swiss labor consultation as it deepens strategic focus into a dedicated radiopharmaceuticals company. Spurred by encouraging Phase 1/2a data for lead DLL3-targeting Radio-DARPin MP0712 (co-developed with Orano Med) in small cell lung cancer, the company is streamlining internal operations to extend its CHF 57.5M ($69M USD) cash runway into late 2027.
Swiss biotech Molecular Partners initiated a restructuring cutting up to 55 roles (~44% of headcount) to transform into a dedicated targeted radiopharmaceuticals developer, prioritizing lead clinical DLL3 Radio-DARPin MP0712 co-developed with Orano Med.
Chief Executive Officer & Co-Founder
SVP Finance & Executive Management
SVP Biology
No active job listings. Check back later.